ArticleMedicine2026
The dual crisis of coronary thrombosis and sepsis in JAK2-mutated essential thrombocytosis: A clinical case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleEssential thrombocytosis (ET) is a myeloproliferative neoplasms (MPNs) primarily caused by JAK2 gene mutations. The condition is characterized by thrombosis or hemorrhage as its main complications, with infection posing a significantly elevated risk of mortality. The dual crisis of acute myocardial infarction and sepsis occurring simultaneously is extremely rare but fatal. Identifying and properly managing these rare yet severe complications is of paramount importance. This case report aims to emphasize the importance of timely identification of primary thrombocytosis and correct intervention of acute myocardial infarction and sepsis complications, especially early coronary angiography stent placement, anticoagulation-hemorrhage and sepsis management, which can not only improve patient prognosis but also effectively reduce the risk of death. DIAGNOSES: A 79-year-old female patient presented with palpitations and abdominal pain. An electrocardiogram showed ST-segment elevation in the inferior and anterior walls, indicating a ST-segment elevation myocardial infarction (STEMI). The elevated white blood cell count (36.92 × 109/L) and procalcitonin (PCT) level (6.26 ng/mL) indicated septicemia markers, while imaging studies revealed intestinal gas accumulation and ascites; sepsis was confirmed. The platelet count peaked at 1357 × 109/L, and genetic testing for MPNs revealed an 80% mutation in JAK2 V617F, ET was confirmed.
interventionsEmergency coronary stent implantation was performed, along with piperacillin-tazobactam antibiotic therapy and controlled fluid resuscitation. Treatment included antiplatelet therapy, anticoagulation therapy, and hydroxyurea. OUTCOMES: The patient's condition improved, with complete disappearance of symptoms of palpitations and abdominal pain, normal infection indicators, and smooth discharge. One month later, the platelet decreased to 439 × 109/L, and no bleeding or thrombosis complications occurred. LESSONS: This case suggests that JAK2 gene testing should be conducted for unexplained thrombocytosis; occult infection must be investigated when myeloproliferative neoplasm patients develop leukocytosis; maintaining therapeutic balance is crucial in the dual crisis of thrombosis and sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.